课题基金 / 基金详情

Surfaceome CRISPR screening for SARS-CoV-2 virulent proteins

Surfaceome CRISPR screening for SARS-CoV-2 virulent proteins
表面组 CRISPR 筛选 SARS-CoV-2 毒力蛋白
批准号:
10892771
负责人:
Sanghyun Lee
金额:
$16.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
未结题
起止时间:
2016-06-01 至 2026-07-31

项目摘要

项目成果

Sanghyun Lee的其他基金

相似基金

相关文献

中文摘要
翻译
严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)是冠状病毒的病原体
英文摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19). Spike protein is the primary antigenic target for COVID vaccines and interfering with the interface between RBD (Receptor Binding Domain) of spike and ACE2 is the mechanism of action for the majority of existing therapeutic antibodies, indicating the importance of RBD and its binding to the cellular receptor for controlling SARS-CoV-2. It is unclear whether there are any intrinsic cellular proteins that inhibit viral entry of SARS-CoV-2. Our new preliminary data reveal that cellular entry of SARS-CoV-2 is inhibited by a novel inhibitory cellular protein, Leucin-rich repeat containing 15 (LRRC15). We generated a focused CRISPR activation (CRISPRa) library, named surfaceome, that covers all ~6000 known/predicted surface proteins on the cellular plasma membrane. The surfaceome CRISPRa screening was performed by staining cells with a recombinant spike protein to identify SARS-CoV-2 binding factors. Strikingly, LRRC15 inhibits spike-mediated viral entry not only in the same cells, but also in neighboring cells in trans. Expression of LRRC15 in ACE2+ cells blocked spike-mediated viral entry in ACE2+LRRC15- cells, providing a unique concept of viral entry inhibition by an inhibitory factor. This result suggests a protective role of LRRC15 in a physiological context. Our central hypothesis is that human LRRC15 acts as an inhibitory entry factor for SARS-CoV-2, acting in trans as a decoy receptor expressed in non-susceptible pathological fibroblasts in the lung. This proposal will explore the mechanism by which LRRC15 inhibits entry of SARS-CoV-2 in trans through three subaims of Aim 1. We will leverage the screening platform to identify cellular receptors for secreted virulence proteins of SARS-CoV-2, Orf3a, Orf7a, and Orf8. Importantly, the same screening platform is validated to be a efficient platform for secreted virulent proteins. In a separate screening for norovirus secreted virulence protein (NS1), the surfaceome screening successfully identified Syndecan-4 as a putative cellular receptor for norovirus NS1 (Li et al., In preparation). In the Aim 2, we will perform a surfaceome screening for Orf3a, Orf7a, and Orf8 and will discover putative cellular receptors for the secreted virulence proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Entry inhibition of SARS-CoV-2 by human LRRC15
  • 批准号:
    10575888
  • 项目类别:
  • 资助金额:
    $21.73万
  • 财政年份:
    2023
  • 负责人:
    Sanghyun Lee
  • 依托单位:
Surfaceome CRISPR screening for SARS-CoV-2 virulent proteins
  • 批准号:
    10891755
  • 项目类别:
  • 资助金额:
    $19.87万
  • 财政年份:
    2022
  • 负责人:
    Sanghyun Lee
  • 依托单位:
A Secreted Viral Protein Determines Norovirus Persistence By Immune Evasion
  • 批准号:
    10219936
  • 项目类别:
  • 资助金额:
    $24.5万
  • 财政年份:
    2020
  • 负责人:
    Sanghyun Lee
  • 依托单位:
A Secreted Viral Protein Determines Norovirus Persistence By Immune Evasion
  • 批准号:
    10186953
  • 项目类别:
  • 资助金额:
    $24.83万
  • 财政年份:
    2020
  • 负责人:
    Sanghyun Lee
  • 依托单位:
国内基金
海外基金
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
  • 批准号:
    JCZRLH202600625
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
  • 批准号:
    2026JJ50619
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    翁春艳
  • 依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介 导“肠-胰岛 ”轴血糖调控功能的降糖机制研 究
  • 批准号:
    Y24H280055
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    颜美秋
  • 依托单位: